Clinical Trials Sponsored by Nordic Bioscience A/S

Total 1546 results

Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (paradigm™7)

Congenital Bleeding Disorder | Haemophilia B

United States, Switzerland, Germany
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times

Healthy Volunteers Type 2 Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Persons With Obesity (PwO) Exploratory Research

Obesity

India
Novo Nordisk A/S

Completed

A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

Type 2 Diabetes | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY) (SURE GERMANY)

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa (PACT-MEA)

Diabetes Mellitus, Type 2

Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa, United Arab Emirates
Novo Nordisk A/S

Completed

A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE) (MIRAGE)

Diabetes Mellitus, Type 2

North Macedonia
Novo Nordisk A/S

Completed

A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

Diabetes Mellitus, Type 2 | Healthy Volunteers

China
Novo Nordisk A/S

Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) (SURE NL)

Diabetes Mellitus, Type 2

Netherlands
Novo Nordisk A/S

Completed

Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes (EXPECT)

Diabetes | Diabetes Mellitus, Type 1

Israel, Italy, Russian Federation, United Kingdom, Denmark, Austria, Serbia, Canada, Croatia, Australia, Greece, Ireland, Brazil, Spain, Argentina
Novo Nordisk A/S

Completed

Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy

Postmenopausal Vaginal Atrophy

Denmark
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) (DUAL™ I China)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

Obesity

Mexico
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Novo Nordisk A/S

Withdrawn

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity (PIONEER START)

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia (SPIRIT)

Diabetes Mellitus, Type 2

Colombia
Novo Nordisk A/S

Completed

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works

Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

French National Registry of Children Born Small for Gestational Age Treated With Somatropin

Small for Gestational Age | Growth Disorder

France
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (PIONEER 1)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Mexico, Japan, Serbia, Turkey, Italy, Czechia, Bulgaria, Algeria, Romania
Novo Nordisk A/S

Completed

Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific (ACTION-APAC)

Obesity

Pakistan, Bangladesh, India, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam
Novo Nordisk A/S

Completed

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 6)

Obesity | Overweight

Japan, Korea, Republic of
Novo Nordisk A/S

Withdrawn

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes (SUSTAIN SWITCH)

Diabetes Mellitus, Type 2

United States, Sweden, Austria, Finland
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 4)

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Spain, Netherlands, Sweden, Switzerland, South Africa, Denmark, Portugal, Ukraine
Novo Nordisk A/S

Completed

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Diabetes Mellitus, Type 2

United States, Italy, Canada, Germany, Czechia
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
Novo Nordisk A/S

Completed

Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant

Obesity | Overweight

Canada
Novo Nordisk A/S

Completed

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

Non-alcoholic Fatty Liver Disease | Hepatobiliary Disorders

Germany
Novo Nordisk A/S

Completed

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1)

Overweight or Obesity | Metabolism and Nutrition Disorder

United States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico
Novo Nordisk A/S

Completed

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

Congenital Bleeding Disorder | Haemophilia A

Japan
Novo Nordisk A/S

Completed

A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors (explorer™4)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Austria, Spain, Japan, Croatia, Italy, United Kingdom, Israel, Sweden, Ukraine, Malaysia, Greece, Denmark, Canada
Novo Nordisk A/S

Completed

Injection Site Pain Comparison of Excipient Solutions

Obesity

Netherlands
Novo Nordisk A/S

Completed

A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates (INTENSIFY)

Diabetes Mellitus, Type 2

United Arab Emirates
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine (VIEW-Iran)

Diabetes Mellitus, Type 2

Iran, Islamic Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes (Ellipse™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Russian Federation, Spain, United Kingdom, Austria, Belgium, Mexico, Sweden, Israel, Taiwan, Hungary, Malaysia, Serbia, Turkey, Denmark, Greece, Thailand, North Macedonia, Norway, Portugal, Germany, Romania and more
Novo Nordisk A/S

Completed

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Italy, Poland, Russian Federation, United Kingdom, Canada, Denmark, Sweden, Austria, Belgium, Spain, Ireland, Norway, Serbia, Finland, Portugal, Ukraine
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Diabetes | Type 2 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (SUSTAIN)

Diabetes Mellitus, Type 2 | Diabetes

Taiwan, Korea, Republic of, South Africa, Hong Kong, Brazil, China, Ukraine
Novo Nordisk A/S

Completed

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice (ARISE)

Diabetes Mellitus, Type 2

Malaysia, South Africa, Philippines, Australia, India, Saudi Arabia
Novo Nordisk A/S

Completed

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets

Type 2 Diabetes | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Healthy Volunteers Diabetes Mellitus, Type 2 | Healthy Volunteers Overweight | Healthy Volunteers Obesity

Netherlands
Novo Nordisk A/S

Completed

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (PIONEER 9)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (SWITCH PRO)

Diabetes Mellitus, Type 2

United States, Slovakia, Canada, South Africa, Puerto Rico, Poland
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark, Sweden
Novo Nordisk A/S

Completed

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...

3

Subscribe